Royalty Report: Drugs, Cancer, Therapeutic – Collection: 236353

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Disease
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 233450

License Grant
The Parties intend to develop in Asia a therapeutic product containing glufosfamide for the treatment of cancer.

The Japanese Licensor grants an exclusive license to Licensors Know-How to make, have made, use, offer to sell, sell and import Compound Product throughout the world.

License Property
The Compound shall mean glufosfamide.

The Compound Product shall mean any product that was developed by Licensee or a sublicensee of Licensee for marketing as a therapeutic that contains the Compound and that is for the treatment of cancer.

Field of Use
The Field shall mean all human cancer therapeutic uses.

IPSCIO Record ID: 236353

License Grant
The Parties intend to develop in Asia a therapeutic product containing glufosfamide for the treatment of cancer.

The Japanese Licensor grants an exclusive license to Licensors Know-How to make, have made, use, offer to sell, sell and import Compound Product throughout the world.

License Property
The Compound shall mean glufosfamide.

The Compound Product shall mean any product that was developed by Licensee or a sublicensee of Licensee for marketing as a therapeutic that contains the Compound and that is for the treatment of cancer.

Field of Use
The Field shall mean all human cancer therapeutic uses.

IPSCIO Record ID: 6928

License Grant
The Licensor entered into an exclusive License Agreement with the Licensee, granting exclusive worldwide rights to develop and commercialize glufosfamide for the treatment of cancer in humans and animals, and certain other uses.
License Property
Glufosfamide is a drug candidate that shares certain structural characteristics with glucose but acts instead as a chemotherapeutic agent when taken up by a cell.
Field of Use
The Licensee is responsible for the development, manufacturing and marketing of glufosfamide and will bear all costs associated with development, commercialization and patent prosecution, and will control product development and commercialization. In addition, the Licensee will be responsible for all royalty and milestone payments due under the Baxter License development Agreement.

The rights granted apply to the drug industry relating to the healthcare market.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.